Building healthier futures powered by thoughtful science
We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.
Advancing rare disease research
Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
From our blog
News / February 7, 2025
NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation
News / February 7, 2025
The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs
Press Release / January 27, 2025
Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.
News / February 7, 2025
NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation
News / February 7, 2025
The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs
Press Release / January 27, 2025
Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.
Chocolate, camaraderie & a little extra sweetness!
Today, the team took a well-deserved break to indulge in some sweet treats together. Every day is a good day in the NSP office—but we won’t deny that chocolate fondue makes it even better!
Today, we celebrate the brilliant #WomenInScience who push the boundaries of innovation and discovery every day! 💙
A BIG shout-out to all the #WomenInSTEM. Let's continue to break barriers & pave the way for the next generation! https://x.com/NSPharmaInc/status/1889328894890623177/photo/1
For those living with NLRC4 mutation and XIAP deficiency, the wait for effective treatments has been long and challenging - but change IS on the horizon!
Another significant step forward for the Duchenne community! This recognition moves us closer to delivering meaningful progress and hope to those impacted. 🚀
Read more about it here: https://www.nspharma.com/press-releases